Drug Profile
Lu AF 28996
Alternative Names: Lu AF-28996Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Lundbeck A/S
- Class Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action Dopamine D1 receptor agonists; Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Parkinson's disease
Most Recent Events
- 29 Mar 2024 Lundbeck A/S plans a pharmacokinetics phase I trial (In volunteers) in UK (PO) in April 2024 (NCT06337110),
- 27 Feb 2024 Lundbeck initiates a phase I pharmacokinetics trial (In volunteers) in USA (PO, Capsule) (NCT06277609)
- 26 Feb 2024 H. Lundbeck plans a phase I pharmacokinetics trial (In volunteers) (PO, Capsule) in February 2024 (NCT06277609)